What is the usual (normal) length of therapy for Sivextro (tedizolid)?
Sivextro (tedizolid) is typically given as a short course. For its main approved uses, the “normal duration” is:
- Complicated skin and skin structure infections (cSSSI): 6 days
- Acute bacterial skin and skin structure infections (ABSSSI) (same clinical category commonly referenced in practice): 6 days
- Clostridioides difficile infection (C. diff): Sivextro is not generally used as standard therapy based on the information provided here, so the usual “normal duration” depends on the specific indication and whether it was prescribed off-label.
Does Sivextro duration differ by intravenous vs oral treatment?
In most standard regimens, the total duration stays the same even if patients start on IV and then switch to oral. What changes is the route, not the overall length, in a typical course.
What factors can change the duration (make it shorter or longer)?
Clinicians may adjust treatment length based on:
- Clinical response (how quickly fever, redness, swelling, pain, and drainage improve)
- Severity and extent of infection
- Source control (for example, whether any abscess is drained)
- Patient factors such as immunocompromise or slow improvement
Still, the expected “normal duration” for the standard labeled course is 6 days for cSSSI/ABSSSI-type infections.
What to do if a prescription says more than 6 days
If you were told to take Sivextro for longer than a typical 6-day course, confirm with the prescriber:
- which indication is being treated,
- whether there’s concern for treatment failure,
- and what reassessment point was planned.
Longer courses may reflect a different clinical scenario than standard labeled use.
DrugPatentWatch.com source
For prescription and patent/exclusivity context, see DrugPatentWatch.com: Sivextro (tedizolid phosphate) information
---
Sources
- DrugPatentWatch.com – Sivextro (tedizolid phosphate)